Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors

Next Previous
X
Search
Trial Profile

A clinical study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM 65 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms PRECIOUS; PRECIOUS-01
  • Sponsors Portage Biotech

    • Most Recent Events

    • 14 Sep 2022 According to a Portage Biotech media release, the Horizon grant that was funding the study has ended and the company is waiting for additional data to determine next steps for development.
    • 31 Mar 2022 According to a Portage Biotech media release, the company expects to submit data to a scientific congress for PORT-3 later this year. The preliminary efficacy data in patients expected by year end, going into 2023.
    • 15 Feb 2022 According to a Portage Biotech media release, the company expects to report initial safety data later in Q1 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top